COVID rebound after Pfizer treatment likely due to robust immune response, study finds
By Leroy Leo and Julie Steenhuysen (Reuters) – A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday. They concluded that taking a longer course of the drug – beyond the recommended five … Read more